Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review on the current knowledge and use of Single-cell RNA Sequencing in Head and Neck Cancer

    Research output: Contribution to journalReviewResearchpeer-review

  5. Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

OBJECTIVES: Comorbid conditions impact outcome for patients treated for oropharyngeal squamous cell carcinoma (OPSCC) and serve as competing risk factors for death. The purpose of this study was to examine differences in comorbidities in patients with OPSCC and known HPV-DNA.

MATERIAL AND METHODS: We included patients diagnosed with OPSCC in Eastern Denmark in 2000-2014. Patients were linked to the Danish National Patient Register to identify comorbidities based on the Charlson Comorbidity Index (CCI) at time of diagnosis and following cancer treatment. Patients were age-and sex-matched in a 1:10 ratio with a reference group and stratified according to HPV-status.

RESULTS: In total 1,499 patients (55.0% HPV+) and 14,990 controls were included. Significantly more HPV+ patients had no comorbidities compared to HPV- patients at time of diagnosis (RR: 1.5 (1.3;1.6), n = HPV+: 522, HPV-: 302) and following treatment (RR 1.5 (1.4;1.6), n = HPV+: 342, HPV-: 142). Most prevalent comorbidity was malignancy not including OPSCCs. HPV+ patients had an increased risk of having AIDS before their OPSCC diagnosis compared to the reference population (OR: 4.8 (1.8;12.9)). HPV- patients had increased risk of multiple comorbidities including cerebrovascular disease (OR: 1.9 (1.4;2.5)), peripheral vascular disease (OR: 1.7 (1.9;3.7)), dementia (OR: 2.9 (1.4;5.8)), ulcer disease (OR: 2.6 (1.9;3.5)), liver disease, mild (OR: 9.5 (7.0;13.0)) and severe (OR: 13.9 (5.8;22.8)).

CONCLUSION: This study showed that HPV- patients had more comorbidities than HPV+ patients at the diagnosis time and following treatment. Irrespective of HPV-status, OPSCC patients had a significant increased risk of (secondary) malignancy compared to the reference population.

Original languageEnglish
JournalOral Oncology
Volume96
Pages (from-to)1-6
Number of pages6
ISSN1368-8375
DOIs
Publication statusPublished - 1 Sep 2019

    Research areas

  • Charlson Comorbidity Index (CCI), Comorbidity, Human papillomavirus, Oropharyngeal cancer

ID: 58346344